Boston Scientific Corp Receives a Buy from BMO Capital

By Jason Carr

BMO Capital analyst Joanne Wuensch reiterated a Buy rating on Boston Scientific Corp (NYSE: BSX) on June 19 and set a price target of $30. The company’s shares closed yesterday at $28.01, close to its 52-week high of $28.51.

According to, Wuensch is a 5-star analyst with an average return of 11.7% and a 78.5% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Edwards Lifesciences.

Currently, the analyst consensus on Boston Scientific Corp is Moderate Buy and the average price target is $29.13, representing a 4.0% upside.

In a report issued on June 9, RBC Capital also reiterated a Buy rating on the stock with a $31 price target.

Boston Scientific Corp’s market cap is currently $38.35B and has a P/E ratio of 87.53. The company has a book value ratio of 5.4371.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. Its products and technologies are used to diagnose or treat medical conditions, including heart, digestive, pulmonary, vascular, urological, women’s health and chronic pain conditions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.